A composition for internal imaging of a subject includes an imaging contrast agent and one or more carrier agents that can pass through cellular and tissue membranes. Examples of imaging contrast agents are iodine-based, silver-based, or barium-based. Examples of carrier agents are dimethyl sulfoxide, urea, or an alcohol. Methods for internally imaging a subject using such a composition are also disclosed.

Disclosed herein are novel procedures, systems and excipient solutions for in situ provision of a contrast media at a user defined concentrations. An automated procedure according to embodiments of the current invention provides increased user safety, flexibility and user friendliness.

The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAA9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.

The present invention relates to a method for preparing an X-ray contrast agent iomeprol and, more specifically, to a method for preparing iomeprol by adding an inorganic base, an inorganic chloride, a solvent, etc. to 5-(2-hydroxyacetamido)-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (1b) to cause N-methylation reaction, thereby enabling easy separation and removal of inorganic salts generated during the reaction, without treatment with an ion exchange resin, while reducing the conventional production time, and minimization of the amount of reaction impurities.

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein.

An imaging contrast composition comprising an iodinated contrast agent and a ligand secured to the iodinated contrast agent is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing iodinated radiocontrast agents from a patient is disclosed, the method comprising providing an iodinated radiocontrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the iodinated radiocontrast agent to the patient; conducting procedure CT scan or procedure using fluoroscopy; and sequestering the iodinated radiocontrast agent on the capture substrate.

The present invention relates to a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. In the formula (1), R.sup.1 to R.sup.3 are each independently a predetermined amino group or a predetermined amide group, or a group represented by the formula (2), and at least one of R.sup.1 to R.sup.3 is a group represented by the formula (2).

##STR00001##

The invention describes a method to differentiate tumour tissue from brown adipose tissue on a PET-CT scan. In particular, the invention concerns a method for discriminating primary tumour and/or metastases from brown and/or beige adipose tissue, by PET-CT imaging, in a human cancer patient.

The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAAV9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.

The present invention relates to injectable compositions. More particularly, the present disclosure relates to injectable, thermogelling hydrogel formulations comprising at least one antibiotic for relieving and/or treating low back pain.